title: Reduced-fluence photodynamic therapy combined with ranibizumab for nonproliferative macular telangiectasia type 2.
abstract: OBJECTIVE
  To report the efficacy of reduced-fluence photodynamic therapy (PDT) combined with intravitreal ranibizumab for the treatment of nonproliferative macular telangiectasia (MacTel) type 2.
  
  
  METHODS
  Noncomparative, interventional, retrospective case series; 5 eyes of 4 patients were studied. Patients were treated with reduced-fluence PDT and intravitreal ranibizumab within 24 h. After initial treatment, follow-up was at least 12 months in all patients.
  
  
  RESULTS
  At baseline median logMAR (logarithm of the minimal angle of resolution) best-corrected visual acuity (BCVA) was 1.0 (range, 1.0-0.3). At 3 months of follow-up vision increased in 3 out of 5 eyes and median BCVA was 0.4 (range, 1.0-0.2). The gain of BCVA ranged from 6 lines to 1 line. Visual acuity remained stable in the other 2 study eyes. No eyes lost vision at 3 months of follow-up. At 12 months of follow-up median logMAR BCVA was 0.7 (range, 1.3-0.3). Two eyes had maintained their gain in BCVA compared to baseline. Two eyes lost vision compared to baseline and 1 eye showed unchanged visual acuity at 12 months of follow-up.
  
  
  CONCLUSIONS
  A combination therapy with reduced-fluence PDT and intravitreal ranibizumab might be a valuable treatment option for eyes with progressive vision loss due to nonproliferative MacTel type 2.
authors.affiliation: Department of Ophthalmology, Innsbruck Medical University, AT-6020 Innsbruck, Austria. claus.zehetner@i-med.ac.at
authors.forename: Claus
authors.initials: C
authors.lastname: Zehetner
authors.forename: Gertrud
authors.initials: G
authors.lastname: Haas
authors.forename: Bernhard
authors.initials: B
authors.lastname: Treiblmayr
authors.forename: Gerhard F
authors.initials: GF
authors.lastname: Kieselbach
authors.forename: Martina T
authors.initials: MT
authors.lastname: Kralinger
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D058449:Intravitreal Injections; D008266:Macula Lutea / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000627:therapeutic use; D000069579:Ranibizumab; D058456:Retinal Telangiectasis / Q000175:diagnosis / Q000188:drug therapy*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D017319:Photosensitizing Agents; D000069579:Ranibizumab